XTX Topco Ltd Increases Stake in Indivior PLC

XTX Topco Ltd has significantly increased its investment in Indivior PLC (NASDAQ:INDV) by an impressive 763.4% during the third quarter. This information comes from XTX's recent 13F filing with the Securities and Exchange Commission (SEC). After acquiring an additional 117,767 shares, XTX Topco Ltd now holds a total of 133,194 shares in Indivior, which accounts for about 0.10% of the company. The value of this stake was approximately $1,299,000 as reported in the latest filing.

In addition to XTX Topco Ltd, other institutional investors have also adjusted their positions in Indivior recently. For example, Iron Triangle Partners LP established a new stake valued at around $8,243,000 in the third quarter. Similarly, Krensavage Asset Management LLC took a new position worth $6,843,000 during the same period. Moreover, Millennium Management LLC increased its stake by 48.1% in the second quarter, bringing its total holdings to 493,313 shares valued at $7,952,000 after an additional purchase of 160,282 shares. Other notable investors include Stonepine Capital Management LLC and Clark Estates Inc. NY, who also made new acquisitions in the third quarter valued at $2,632,000 and $2,477,000, respectively. Overall, hedge funds and institutional investors own approximately 60.33% of Indivior’s shares.

Analysts Provide New Price Targets

Recently, several analysts have offered their views on Indivior’s stock. For instance, Piper Sandler reaffirmed an "overweight" rating with a price target increase from $15.00 to $16.00 in their note dated October 25th. Meanwhile, Craig Hallum downgraded their price target from $20.00 to $16.00 while maintaining a "buy" rating as of October 11th.

Indivior's Stock Performance

On a recent trading day, shares of Indivior (NASDAQ:INDV) opened at $11.35. The company has a current ratio of 0.83, a quick ratio of 0.65, and a high debt-to-equity ratio of 23.50. Indivior’s market capitalization stands at $1.56 billion and it has a P/E ratio of -283.68, with a beta of 0.75. The stock has seen a 12-month low of $7.33 and a high of $23.22, indicating significant volatility. Currently, its 50-day simple moving average is $9.79, while its 200-day moving average is $12.08.

Indivior announced its latest earnings on October 24th, reporting an EPS of $0.54 for the quarter, which exceeded analysts' expectations of $0.39 by $0.15. The company recorded a revenue of $307.00 million compared to the consensus estimate of $302.25 million. Analysts project that Indivior will achieve an EPS of 1.66 for the current fiscal year.

Company Overview

Indivior PLC, along with its subsidiaries, is involved in the development, manufacturing, and sales of buprenorphine-based prescription medications aimed at treating opioid dependence and related disorders in various regions including the U.S. and the U.K. The company focuses on creating treatments for substance use disorders, serious mental illnesses, and opioid overdose.

Investment Considerations

Before making any investment decisions regarding Indivior, investors may want to be aware of insights provided by market analysts. While Indivior holds a "Buy" rating among some analysts, others suggest looking into alternative stocks that might offer more promising returns based on current trends.

Investing in stocks requires careful consideration of various factors, including market conditions, company performance, and expert recommendations.

Investment, Stocks, Growth